Tirzepatide , a dual GLP-1/GIP receptor agonist, has been approved by NICE for type 2 diabetes management
To minimize these events, Sean Wharton, MD, director of the Wharton Medical Clinic in Toronto, and colleagues suggest the three Es: E ducation and explanation E scalation to an appropriate dose E ffective management of GI side effects. Patients should be counseled on means to decrease adverse event risk such as reducing meal size
Illustration by gemini.google.com
Urine : The same ketones are filtered through your kidneys, which can give urine a sweet or unusual smell if your diet is lower in carbs
The ones physicians and insurers most commonly accept: type 2 diabetes or prediabetes, high blood pressure, high cholesterol, obstructive sleep apnea, PCOS, fatty liver disease, and cardiovascular disease